First Line Trials

1. Study of Efficacy and Safety of Nivolumab in Combination with EGF816 and of Nivolumab in Combinations with INC280 in Patients with Previously Treated NSCLC
 
          ClinicalTrials.gov Identifier:                   NCT02323126         

This study is currently recruiting participants.
 
A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
 
Ontario
Toronto

2. A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

         ClinicalTrials.gov Identifier:                  NCT02185690        

This study is currently active but not recruiting.

MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations. These data suggest that MEK162 may provide a potential benefit in cancer indications harboring these mutations. MEK162 is currently being investigated in phase I clinical testing and has been well tolerated up to an MTD of 45mg BID in cancer patients. 

Alberta
Cross Cancer Institute, Edmonton

Ontario
Juravinski Cancer Centre, Hamilton
The Ottawa Hospital Regional Cancer Centre, Ottawa
Princess Margaret Cancer Centre, Toronto

3. Study to Compare AMG 510 "Proposed INN Sotorasib" with Docetaxel in NSCLC (CodeBreak 200)

      ClinicalTrials.gov Identifier:               NCT043003780     

This study is currently active but not recruiting.
 
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
 
Ontario
Ottawa
Toronto
Hamilton
London
 

4. A Study of Osimertinib with or without Chemotherapy as 1st Line Treatment in Patients with Mutated Epidermal Growth Factor Receptor NSCLC (FLAURA2)
 
        ClinicalTrials.gov Identifier:                 NCT04035486        

This study is currently recruiting participants. 
 
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer.

Alberta
Calgary
Edmonton

Ontario
Toronto
 
Quebec
Montreal

 

5.  A Study of Tiragolumab in Combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin vs. Pembrolizumab plus Penetrexed and Carboplatin/Cisplatin in Participants with Previously Untreated Advanced Non-Squamous NSCLC. (SKYSCRAPER-06)

       ClinicalTrials.gov Identifier:              NCT04619797      

This study is currently recruiting participants. 
 
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

Alberta
Cross Cancer Institute, Edmonton
 
Ontario
Royal Victoria Regional Health Centre, Barrie
Victoria Hospital - London Health Sciences Centre, London
Lakeridge Health, Oshawa
Sault Area Hospital, Sault Ste Marie
Princess margaret Cancer Centre, Toronto
 
Quebec
Universite de Montreal - Hopital Maisonneuve-Rosemount, Montreal
 

 

6. Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrilizumab (MK-3475) with or without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults with Metastatic Nonsquamous NSCLC (MK-7902-006/E7080-G000-315/LEAP-006)

         ClinicalTrials.gov Identifier:                    NCT03829319          

This study is currently recruiting participants
 
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.

Ontario
Juravinski Cancer Centre (Site 0407), Hamilton
Kingston Health Sciences Centre (Site 0414), Kingston
Lakerrdge Health (Site 0406), Oshawa
Sault Area Hospital (Site 0413), Sault Ste Marie

Quebec
Hopital Cite de la Sante de Laval (Site 0400), Laval
CIUSSS l'Ouest de l'Ile de Montreal - St-Marys Hospital (Site 0412), Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0408), Trois-Rivieres  
CHU de Quebec - Universite Laval - Hotel Dieu de Quebec (Site 0403), Quebec  

7. Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

           ClinicalTrials.gov Identifier:                    NCT02576574        

This study is active but not currently recruiting.

The purpose of this study is to demonstrate superiority with regard to progression free survival (PFS) based on an Independent Review Committee (IRC) assessment of avelumab versus platinum-based doublet in non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumours.

New Brunswick 
The Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8

Ontario
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5

8. Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568)

 
            ClinicalTrials.gov Identifer:                        NCT02659059         
 
This study is active but not currently recruiting. 
 
 
The purpose of this study is to determine the objective response rate (ORR) in PD-L1+ stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

Ontario 
Kingston Regional Cancer Centre
Kingston, Ontario, Canada, K7L 2V7
 
Sault Area Hospital
Sault Ste Marie, Ontario, Canada, P6B 0A8
 

Quebec
Csss De St-Jerome 
St. Jerome, Quebec, Canada, J7Z 5T3


9. A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer(NSCLC) (B-FAST)

         ClinicalTrials.gov Identifier:                    NCT03178552         

This study is currently recruiting participants. 

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Alberta
Cross Cancer Institute, Edmonton                                                                           Recruiting

Ontario 
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials       Recruiting
Barrie, Ontario, Canada, L4M 6M2
 
William Osler Health System Brampton Civic Hospital       Recruiting
Brampton, Ontario, Canada, L6R 3J7
 
London Health Sciences Centre · Victoria Hospital; Department of Medicine       Recruiting
London, Ontario, Canada, N6A 5W9
 
Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center       Recruiting
Oshawa, Ontario, Canada, L1G 2B9
 
Sunnybrook Health Sciences Centre        Recruiting
Toronto, Ontario, Canada, M4N 3M5
 
Princess Margaret Hospital; Medical Oncology Dept       Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
Jewish General Hospital; Sir Mortimer B. Davis                                                       Recruiting
Montreal, Quebec, Canada, H2W 1S6
 
IUCPQ (Hôpital Laval)                                                                                              Recruiting
Quebec City, Quebec, Canada, G1V 4G5

Saskatchewan 
Saskatoon Cancer Agency                                                                                       Recruiting
Saskatoon, Saskatchewan, Canada, SK S7N 4H
 
Manitoba 
CancerCare Manitoba; Department of Medical Oncology                                       Recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
 

11. A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy (IPSOS)

        ClinicalTrials.gov Identifier:                  NCT03191786        

This study is active but not currently recruiting. 

This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group [ECOG] performance status of 2-3).
 
New Brunswick
Regional health authority A vitalite health network  
Moncton, New Brunswick, Canada, E1C 8X3
 
Ontario
Ottawa Hospital Research Institute  
Ottawa, Ontario, Canada, K1Y 4E9
 
Sault Area Hospitals  
Sault Ste Marie, Ontario, Canada, P6A 2C4
 
Princess Margaret Cancer Center  
Toronto, Ontario, Canada, M5G 1Z5
 
Quebec
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology        
Montreal, Quebec, Canada, H3T 1E2
 

12. Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)​

        ClinicalTrials.gov Identifier:                     NCT03515837          

This study is active but not currently recruiting. 
 
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status.

The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS.

Ontario
William Osler Health System (Site 0100), Brampton
Sunnybrook Health Sciences, Odette Cancer Centre (Site 0102), Toronto
Princess Margaret Cancer Centre (Site 0104), Toronto
 
Quebec
Jewish General Hospital (Site 0105), Montreal

13. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

         ClinicalTrials.gov Identifier:                    NCT03829332          

This study is currently recruiting participants. 
 
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).
 
Alberta
Cross Cancer Institute (Site 0400)               Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Study Coordinator, 780-432-8762      
 
Ontario
William Osler Health System (Brampton Civic Hospital) (Site 0402)              Recruiting
Brampton, Ontario, Canada, L6R 3J7
Contact: Study Coordinator, 905-494-2120 x 58389   
  
Windsor Regional Cancer Program (Site 0404)              Recruiting
Windsor, Ontario, Canada, N8W 2X3
Contact: Study Coordinator, 519-253-5253      

British Columbia
Lions Gate Hospital (Site 0407)                                                                     Recruiting
North Vancouver, British Columbia, Canada, V7L 2L7
Contact: Study Coordinator, 604-984-5753 

Quebec
McGill University Health Centre (Site 0418)                                                  Recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Study Coordinator, 514-934-1934      

14. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

         ClinicalTrials.gov Identifier:                    NCT03516981        

This study is currently recruiting participants.

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
 
Ontario
Sunnybrook Health Science Centre (Site 0304)              Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955      

The Ottawa Hospital (Site 0306)                                     Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Study Coordinator, 613-737-7700 x 70175

Princess Margaret Cancer Centre (Site 0309)                  Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Study Coordinator, 416-946-4501
 
Quebec
Jewish General Hospital (Site 0307)              Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, 514-340-8222 x 23674   

CIUSSS du Saguenay-Lac-St-Jean (Site 0305)                 Recruiting
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Study Coordinator, 418-541-1234
 

15. TAK-788 as First-line Treatment vs. Platinum-Based Chemotherapy for NSCLC with EGFR Exon 20 Insertion Mutations

          ClinicalTrials.gov Identifier:                   NCT04129502         
 
This study is currently recruiting participants. 
 
The purpose of this study is to compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

British Columbia
BC Cancer Agency, Vancouver

Alberta
Tom Baker Cancer Centre, Calgary

Ontario
William Osler Health System, Brampton
Princess Margaret Hospital, Toronto

Quebec
Hopital du Sacre Coeur de Montreal, Montreal

16. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

         ClinicalTrials.gov Identifier                  NCT02414139        

This study is currently recruiting participants. 

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
 
Nova Scotia
Novartis Investigative Site                               Recruiting
Halifax, Nova Scotia, Canada, B3H 1V7

Ontario
Novartis Investigative Site                               Recruiting
Ottawa, Ontario, Canada, K1H 8L6
 
17. Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
 
         ClinicalTrials.gov Identifier:                    NCT03302234         
 
This study is active but not currently recruiting. 
 
The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.
 
Alberta
Tom Baker Cancer Centre (Site 0119)           
Calgary, Alberta, Canada, T2N 4N2
Contact: Study Coordinator, 403-521-3347
     
Manitoba
CancerCare Manitoba (Site 0106)           
Winnipeg, Manitoba, Canada, R3E 0V9
Contact: Study Coordinator, 204-787-8776      
 
Quebec
CIUSSS du Saguenay-Lac-St-Jean (Site 0115)           
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Study Coordinator, 418-541-1234 x 2840
     
CISSS de la Monteregie-Centre (Site 0100)           
Greenfield Park, Quebec, Canada, J4V 2H1
Contact: Study Coordinator, 450-466-5000 x 3226  
    
CISSS-CA Hotel-Dieu de Levis (Site 0108)   
Levis, Quebec, Canada, G6V 3Z1
Contact: Study Coordinator, 418-835-7121 x 3048   
  
CIUSSS Ouest de l'Ile - St-Mary's Hospital (Site 0107)        
Montreal, Quebec, Canada, H3T 1M5
Contact: Study Coordinator, 514-345-3511 x 3981  
    
St-Jerome Medical Research Inc (Site 0113)    
St-Jerome, Quebec, Canada, J7Z 5T3
Contact: Study Coordinator,  450431102042      
 

18. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

         ClinicalTrials.gov Identifier:                 NCT03631199       

This study is active but not curently recruiting. 

This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy (double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.

Ontario 
Novartis Investigative Site                                 
Toronto, Ontario, Canada, M5G 1Z6
 
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z6

Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2

19. A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

        ClinicalTrials.gov Identifier:                  NCT03052608         

This study is currently recruiting participants. 

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population.

Ontario
Princess Margaret Cancer Centre                               Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
McGill University Health Centre                                 Recruiting
Montreal, Quebec, Canada, H4A 3J1

20. A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive NSCLC (LIBRETTO-431)

        ClinicalTrials.gov Identifier:                  NCT04194944      
 
This study is currently recruiting participants. 
 
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Alberta
Cross Cancer Institute

Ontario
Princess Margaret Hospital, Toronto

 

21. A Study of Novel Anti-cancer Agents in Patients with Previously Untreated NSCLC (MAGELLAN)

 
        ClinicalTrials.gov Identifier:                  NCT03819465     
 
This study is currently recruiting participants. 
 
 
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Alberta
Edmonton

Ontario
Ottawa
Toronto

22. A Study of Amivantamab and Lazertinib Combination Therapy vs. Osimertinib in Locally Advanced or Metastatic NSLC (MARIPOSA)

        ClinicalTrials.gov Identifier:                  NCT0448780       

This study is currently recruiting participants. 
 
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto
Juravinski Cancer Centre, Hamilton

Quebec
McGill University Hospital, Montreal
 

23. A Study of Combination Amivantamab and Carboplatin-Permetrexed Therapy, Compared with Carboplatin-Permetrexed, in Participants with Advanced or Metastatic NSCLC Characterized by EGFR Exon 20 Insertions (PAPILLON)

        ClinicalTrials.gov Identifier:                  NCT04538664      
 
This study is currently recruiting participants. 
 
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

Alberta
Edmonton

Ontario
Ottawa Hospital, Ottawa
Sunnybrook cancer Centre, Toronto

Quebec
McGill Universtiy Helth Centre, Montreal

 

24. Study of Pembrolizumab (MKL-3475) with or without Maintenance Olaparib in Frist-line Metastatic Squamous NSCLC (MK-7339-008/KEYLINK-008)

 
        ClinicalTrials.gov Identifier:                  NCT03976362      
 
This study is currently recruiting participants.
 
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC.
 

Nova Scotia
Nova Scotia Health Authority (Site 0103), Halifax

Ontario
Juravinski Cancer Centre (Site 0107), Hamilton
Kingston Health Sciences Centre (Site 0102), Kingston
Stronach Regional Cancer Centre (Site 0100), Newmarket

Quebec
CISSS de la Monteregie-Centre (Site 0101), Greenfield Park
Hopital Cite de la Sante de Laval (Site 0105), Laval
CIUSSS Ouest de l'Ile - St Mary's Hospital, Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0106), Trois-Rivieres 
 

25. Study of Pembrolizumab with Concurrent Chemorasiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC (MK-7339-012/KEYLYNK-012)

        ClinicalTrials.gov Identifier:                  NCT04380636       
 
This study is currently recruiting participants.

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC.

Quebec
Centre Hopitalier de l'Universite de Montreal - CHUM, Montreal